Creation of Long-Term Physical Stability of Amorphous Solid Dispersions N-Butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide, Resistant to Recrystallization Caused by Exposure to Moisture

Amorphous solid dispersion (ASD) technology is often used as a promising strategy to improve the solubility of active pharmaceutical ingredients (APIs). ASDs allow APIs to be dispersed at the molecular level in a polymer carrier, destroying the crystalline structure of the APIs and, thanks to the polymer, providing long-term supersaturation in solution. However, stability issues are an obstacle to the development of new medications with ASD. In addition to the molecular mobility at elevated temperatures leading to the crystallization of APIs, moisture affects the physical stability of ASD, leading to fractional separation and recrystallization. N-butyl-N-methyl-1-phenylpyrrolo[1,2-a]pyrazine-3-carboxamide (GML-3) is an original API with both anxiolytic and antidepressant activity, but its insolubility in water can negatively affect (influence) bioavailability. Our study aims to create ASD GML-3 with moisture-resistant polymers (Soluplus®, HPC) and assess the stability of the amorphous state of ASD after storage in high humidity conditions. As a result, HPC KlucelTM FX was revealed to be more stable than the brand, providing a high level of API release into the purified water environment and stability after 21 days (3 weeks) of storage in high humidity conditions. © 2025 Elsevier B.V., All rights reserved.

Авторы
Markeev V.B. 1 , Blynskaya Evgenija V. 1 , Alekseev Konstantin V. 1 , Dorofeev Vladimir L. 1 , Marakhova Anna Igorevna 2 , Vetcher Alexandre A. 2, 3
Journal
Номер выпуска
1
Язык
English
Статус
Published
Номер
203
Том
18
Год
2025
Организации
  • 1 Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies, Moscow, Russian Federation
  • 2 Institute of Pharmacy and Biotechnology, RUDN University, Moscow, Russian Federation
  • 3 Institute for Bionic Technologies and Engineering, Sechenov First Moscow State Medical University, Moscow, Russian Federation
Ключевые слова
active pharmaceutical ingredient(s); amorphous solid dispersion; recrystallization
Цитировать
Поделиться

Другие записи

Avatkov V.A., Apanovich M.Yu., Borzova A.Yu., Bordachev T.V., Vinokurov V.I., Volokhov V.I., Vorobev S.V., Gumensky A.V., Иванченко В.С., Kashirina T.V., Матвеев О.В., Okunev I.Yu., Popleteeva G.A., Sapronova M.A., Свешникова Ю.В., Fenenko A.V., Feofanov K.A., Tsvetov P.Yu., Shkolyarskaya T.I., Shtol V.V. ...
Общество с ограниченной ответственностью Издательско-торговая корпорация "Дашков и К". 2018. 411 с.